Better Therapeutics, Inc.

Better Therapeutics, Inc.

OOTC:BTTX
0.00
USD
+0.00
(-99.00%)
-1.08EPS
14.85MMarket Cap

Total Valuation

USD

As of September 30, 2023, Better Therapeutics, Inc. carries a market capitalization of 14.85M, placing it among publicly traded companies globally. Its enterprise value stands at 22.56M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap14.85M
Enterprise Value22.56M

Important Dates

Better Therapeutics, Inc.'s next confirmed earnings release is scheduled for November 16, 2026.

Earnings Date11/16/2026

Share Statistics

As of September 30, 2023, Better Therapeutics, Inc. has 40.58M shares outstanding.

Shares Outstanding40.58M

Valuation Ratios

These figures are as of September 30, 2023.

PB Ratio-1.49
P/TBV Ratio-1.17
P/FCF Ratio-0.41
P/OCF Ratio-0.41

Financial Position

As of September 30, 2023, Better Therapeutics, Inc. maintains a current ratio of 0.57, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -143.98, indicating conservative leverage, while an interest coverage ratio of -13.58 demonstrates limited ability to service its debt obligations.

Current Ratio0.57
Quick Ratio0.51
Debt / Equity-143.98
Debt / EBITDA-0.54
Interest Coverage-13.58

Financial Efficiency

These figures cover the twelve months ended September 30, 2023. Return on assets (ROA) is negative at -162.15, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 54.00, a quick read on workforce productivity versus industry peers.

Return on Assets (ROA)-162.15
Employee Count54.00

Taxes

USD

Over the twelve months ended September 30, 2023, Better Therapeutics, Inc. recorded 9,000.00 in income tax expense. The company reported a pretax loss of -31.56M and -31.57M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax9,000.00

Stock Price Statistics

As of the close on November 12, 2026, Better Therapeutics, Inc.'s stock has declined approximately 99.00% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.

52-Week Price Change-99.00%

Income Statement

USD

Over the twelve months ended September 30, 2023, Better Therapeutics, Inc. generated - - in revenue and converted that into -31.57M in net income, yielding earnings per share of -1.08. EBITDA reached -26.50M, while operating income came in at -29.61M.

Operating Income-29.61M
Pretax Income-31.56M
Net Income-31.57M
EBITDA-26.50M
EBIT-29.61M
Earnings Per Share (EPS)-1.08

Balance Sheet

USD

As of September 30, 2023, Better Therapeutics, Inc. holds 6.60M in cash and equivalents against 14.31M in total debt, resulting in a net debt position of 7.71M. Total book value stands at -9.94M, with working capital of -5.59M providing operational flexibility.

Cash & Cash Equivalents6.60M
Total Debt14.31M
Net Debt7.71M
Equity (Book Value)-9.94M
Book Value Per Share-0.24
Working Capital-5.59M

Cash Flow

USD

Better Therapeutics, Inc. produced -26.08M in operating cash flow over the twelve months ended September 30, 2023. After subtracting -45,000.00 in capital expenditures, free cash flow totaled -26.13M - equivalent to -0.89 per share.

Operating Cash Flow-26.08M
Capital Expenditures-45,000.00
Free Cash Flow-26.13M
FCF Per Share-0.89

Dividends & Yields

These figures cover the twelve months ended September 30, 2023. Free cash flow yield is negative at -243.47: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -78.74, meaning Better Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-78.74
FCF Yield-243.47

Scores

As of September 30, 2023, Better Therapeutics, Inc. has an Altman Z-Score of -36.45, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-36.45